Free Trial
NASDAQ:CLDX

Celldex Therapeutics Q4 2024 Earnings Report

Celldex Therapeutics logo
$18.30 +0.50 (+2.81%)
Closing price 04/17/2025 04:00 PM Eastern
Extended Trading
$18.55 +0.25 (+1.37%)
As of 04/17/2025 05:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Celldex Therapeutics EPS Results

Actual EPS
-$0.71
Consensus EPS
-$0.73
Beat/Miss
Beat by +$0.02
One Year Ago EPS
N/A

Celldex Therapeutics Revenue Results

Actual Revenue
$1.18 million
Expected Revenue
$1.25 million
Beat/Miss
Missed by -$72.00 thousand
YoY Revenue Growth
N/A

Celldex Therapeutics Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Thursday, February 27, 2025
Conference Call Time
9:30AM ET

Upcoming Earnings

Celldex Therapeutics' Q1 2025 earnings is scheduled for Monday, May 5, 2025, with a conference call scheduled at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Celldex Therapeutics Earnings Headlines

Celldex initiated with an Overweight at Morgan Stanley
Claim Your FREE Protection Guide
In the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code... And since then, "in the know" patriots have quietly used this same "Trump loophole" to shield their life savings from the economic chaos. But with Trump now forcefully bringing back millions of manufacturing jobs from Mexico, China, and the entire BRICS anti-dollar coalition...
Celldex presents preclinical data from CDX-622 at AAAAI 2025
See More Celldex Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Celldex Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Celldex Therapeutics and other key companies, straight to your email.

About Celldex Therapeutics

Celldex Therapeutics (NASDAQ:CLDX), a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

View Celldex Therapeutics Profile

More Earnings Resources from MarketBeat